Lenox Wealth Advisors’s Krystal Biotech KRYS Stock Holding History

Lenox Wealth Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-400	Closed	-$22K	–	869
2019 Q4	$22K	Buy	+400	New	+$19.6K	﹤0.01%	321

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Lenox Wealth Advisors's KRYS Position: Q1 2020 in Review

Lenox Wealth Advisors sold out of Krystal Biotech (KRYS) in Q1 2020, closing a stake of 400 shares — an estimated $22K sold.

Lenox Wealth Advisors first reported a position in KRYS in Q4 2019 and held it in 1 quarter. The position peaked at $22K in Q4 2019. 90 funds tracked by Wall St. Rank hold KRYS as of Q1 2020.

Lenox Wealth Advisors reported no remaining Krystal Biotech position as of Q1 2020 after selling out during the quarter.
Lenox Wealth Advisors sold 400 Krystal Biotech shares in Q1 2020, an estimated $22K.
Lenox Wealth Advisors first reported a position in Krystal Biotech in Q4 2019 and held it in 1 quarter.
Lenox Wealth Advisors's Krystal Biotech position peaked at $22K in Q4 2019.
90 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2020.

Based on Lenox Wealth Advisors's 13F filing for Q1 2020, filed 3 Apr 2020.